PHARVARIS NV (PHVS) Stock News

USA - Nasdaq - NASDAQ:PHVS - NL00150005Y4 - Common Stock

28.38 USD

+0.66 (+2.38%)

Last: 11/28/2025, 7:54:59 PM

28 USD

-0.38 (-1.34%)

After Hours: 11/28/2025, 7:54:59 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

PHVS Latest News, Press Relases and Analysis

All

Press Releases

a day ago - By: The Motley Fool - Mentions: CNTA SKYE TRDA CAMP

What One Fund's Sale of Centessa Stock Signals About the Fast-Rising Biotech Company

10 days ago - By: The Motley Fool - Mentions: HTFL VZ NAMS CDTX ...

Investment Powerhouse Backs Biotech Stock to the Tune of $419 Million

7 months ago - By: Pharvaris N.V.

Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update

18 days ago - By: Pharvaris N.V.

Pharvaris Reports Third Quarter 2025 Financial Results and Provides Business Update

18 days ago - By: Pharvaris N.V.

Pharvaris Reports Third Quarter 2025 Financial Results and Provides Business Update

20 days ago - By: Pharvaris N.V.

Data Supporting the Potentially Differentiated Pharvaris Portfolio Presented at ACAAI 2025 Annual Scientific Meeting

20 days ago - By: Pharvaris N.V.

Data Supporting the Potentially Differentiated Pharvaris Portfolio Presented at ACAAI 2025 Annual Scientific Meeting

a month ago - By: Pharvaris N.V.

Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting

a month ago - By: Pharvaris N.V.

Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting

2 months ago - By: Benzinga - Mentions: EQT NKE WMT UBER

This Uber Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

4 months ago - By: Pharvaris N.V.

Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update

4 months ago - By: Pharvaris N.V.

Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

4 months ago - By: Pharvaris N.V.

Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

4 months ago - By: Pharvaris N.V.

Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

4 months ago - By: Pharvaris N.V.

Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

4 months ago - By: Pharvaris N.V.

Pharvaris Announces Proposed Public Offering of Ordinary Shares

4 months ago - By: Pharvaris N.V.

Pharvaris Announces Proposed Public Offering of Ordinary Shares

5 months ago - By: Pharvaris N.V.

Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025

5 months ago - By: Pharvaris N.V.

Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025

5 months ago - By: Pharvaris N.V.

Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit

5 months ago - By: Pharvaris N.V.

Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit

6 months ago - By: Pharvaris N.V.

Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress

6 months ago - By: Pharvaris N.V.

Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress

6 months ago - By: Pharvaris N.V.

Pharvaris Announces Annual Meeting of Shareholders

6 months ago - By: Pharvaris N.V.

Pharvaris Announces Annual Meeting of Shareholders

6 months ago - By: Pharvaris N.V.

Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema

6 months ago - By: Pharvaris N.V.

Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema

7 months ago - By: Pharvaris N.V.

Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses

7 months ago - By: Pharvaris N.V.

Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses

7 months ago - By: Pharvaris N.V.

Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update

7 months ago - By: Pharvaris N.V.

Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4

7 months ago - By: Pharvaris N.V.

Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4